Turn Therapeutics Q1 net loss $971K; Phase 2 AD trial on track, topline mid-2026

Turn Therapeutics Inc.

2026-Q1 EPS reported -$0.03

Cash and equivalents $11.2M as of March 31, 2026, up from $5.1M at Dec 31, 2025.
Net loss $970,972 ($0.03 basic EPS) vs $328,547 ($0.01) in Q1 2025.
G&A expenses $1.1M, R&D $109K; total op expenses $1.25M.
Avenue Capital facility provides up to $25M; initial $7M funded March 24, 2026; $18M available on milestones.
Phase 2 trial of GX-03 for moderate-to-severe atopic dermatitis; interim analysis Q2 2026, topline mid-2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Turn Therapeutics Inc. reported three months ended March 31, 2026 results: net income $ (970,972 ), EPS $ (0.03 ).

Period: three months ended March 31, 2026
Net income: $ (970,972 )
EPS: $ (0.03 )
Result: reported results

Exact text from the filing

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial results for the three months ended March 31, 2026

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Turn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-054480

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.